Your Global Leader in Stem Cell Market Research
Cell and gene therapy conferences have been rapidly multiplying over the past decade. This article is your ultimate guide to cell and gene therapy conferences worldwide. These conferences include presentations on stem cells, CAR-T, exosomes, and other types of cell and gene therapy applications.
Our goal is for this to be a comprehensive guide to cell and gene therapy events worldwide, so we welcome new additions in the comments below. [Read more…]
DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.
Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]
CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.
On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).
Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]
Cesca Therapeutics is making big moves to become a player in the CAR-T space. In recent months it filed a a patent application for innovation to its CAR-TXpress™ technology, signed a license agreement with China’s IncoCell Tianjin Ltd. for CAR-T related CDMO services in Asia, and is continuing development of Thermogenesis’ novel CAR-TXpress platform.
The company also recently announced the launch of its 2nd gen AXP® II system for isolating and collecting hematopoietic stem cells (HSCs) from umbilical cord blood and peripheral blood. Since the launch of its first AXP® system, Cesca has been a leader is cord blood processing technologies.
